RECRUITINGINTERVENTIONAL

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

Study on Vascular Function, Sarcopenia and Pain in Treated Postmenopausal Osteoporosis

About This Trial

This study aims to follow a cohort of osteoporotic patients treated with anti-osteoporotic drugs and to evaluate the impact of these treatments on the osteoporosis-cardiovascular-sarcopenia triad and on pain.

Who May Be Eligible (Plain English)

Who May Qualify: - Women aged 50 years or older with postmenopausal osteoporosis, whether fractured or not, requiring initiation of treatment with antiosteoporotic drugs (bisphosphonates, raloxifene, teriparatide, denosumab and others to come for this indication, including romosozumab), either orally or by injection, as part of their care and management. - Able to give willing to sign a consent form to participate in research. - Affiliation to a Social Security system. Who Should NOT Join This Trial: - Patient with chronic renal failure, defined as glomerular filtration rate \< 30 mL.min-1 estimated by CKD-EPI. - Patient with a medical and/or surgical history deemed by the investigator or his/her representative to be incompatible with the trial. - Patient under legal protection or deprived of liberty. - Refusal to participate. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Women aged 50 years or older with postmenopausal osteoporosis, whether fractured or not, requiring initiation of treatment with antiosteoporotic drugs (bisphosphonates, raloxifene, teriparatide, denosumab and others to come for this indication, including romosozumab), either orally or by injection, as part of their care and management. * Able to give informed consent to participate in research. * Affiliation to a Social Security system. Exclusion Criteria: * Patient with chronic renal failure, defined as glomerular filtration rate \< 30 mL.min-1 estimated by CKD-EPI. * Patient with a medical and/or surgical history deemed by the investigator or his/her representative to be incompatible with the trial. * Patient under legal protection or deprived of liberty. * Refusal to participate.

Treatments Being Tested

OTHER

Cohort follow-up

* Inclusion medical consultation, * Inclusion clinical examination, * Collection of biological samples (bone biomarkers, epigenetic biomarkers (microRNA)) and analysis of microbiota and genotyping, * Calculation of the Kauppila score on profile spine radiographs by the rheumatologist, * Cardiovascular investigations (FMD, "Flow-Mediated Dilation"); measurement of digital volume increase (RHI, "Reactive hyperhemia index"); measurement of microcirculatory perfusion of the skin at the hand (FLD, "Flow Laser Doppler") ; measurement of the stiffness of the main arteries (aorta) by the Pulse Wave Velocity (PWV), * Exploration of sarcopenia: questionnaires and tests: SARC-F, SPPB, muscle strength, * Quality of life component questionnaires Pittsburgh Sleep (PSQI), Numerical Scale (NS), Brief Pain Inventory (BPI), Hospital Anxiety and Depression scale (HADs), and 36-Item Short Form Survey (SF-36) Quality of Life Questionnaire.

Locations (1)

CHU de Clermont-Ferrand

Clermont-Ferrand, France